Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace
Ali Bozorgi/LinkedIn
Jul 10, 2026, 20:12

Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace

Ali Bozorgi, Dean of Tehran Heart center EP ward, Cardiac Electrophysiologist, Director of EP Fellowship program at Tehran University of Medical Sciences, Tehran Heart Center, Cardiologist at Tehran University of Medical Sciences, shared a post on LinkedIn:

“Delighted to share that an independent editorial has been published in EP Europace (ESC Journals) discussing our recent meta-analysis on oral anticoagulation after atrial fibrillation ablation.

The editorial, authored by Prof. Giuseppe Boriani, Dr. Gianluca Botto, and Dr. Davide Antonio Mei from the University of Modena and Reggio Emilia, offers a thoughtful synthesis of our findings alongside the two recent randomized trials in this space, ALONE-AF and OCEAN.

Key takeaways from the editorial:

  • Our meta-analysis of 31 studies and over 50,000 patients showed that in patients with CHA₂DS₂-VASc score of at least 2, continuation of OAC after successful AF ablation was associated with approximately 50% reduction in stroke and TIA risk (with no between-study heterogeneity).
  • The editorial highlights that both ALONE-AF and OCEAN enrolled predominantly low-risk populations, with only about one-third of participants having CHA₂DS₂-VASc score of at least 3, leaving them underpowered to detect meaningful differences in stroke outcomes.
  • ALONE-AF recorded only 9 primary outcome events over 2 years; OCEAN was terminated early for futility and used a reduced-dose rivaroxaban regimen.
  • Bottom line from the editorial: ‘A successful AF ablation modifies rhythm; it does not necessarily eliminate risk.’ In patients with CHA₂DS₂-VA score of at least 2, oral anticoagulation should remain a cornerstone of long-term management, regardless of apparent procedural success, in line with the 2024 ESC Guidelines.

Grateful to see our work contributing to this important clinical conversation, and thankful to the editorialists for their rigorous and balanced appraisal.

Special thanks once again to Dr. Ehsan Amini-Salehi for his dedication throughout, and to my co-authors including Prof. Arash Arya.

Title 1: Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials

Authors: Sandeep Samethadka Nayak, Ehsan Amini-Salehi, Negin Letafatkar, Arash Arya, Shahriar Ghodous, Maryam Jafari, Amir Nasrollahizadeh, Anoop Gurram, Javad Nadali, Seyedeh Mohadese, Mosavi Mirkalaie, Anya Patel, Payam Kabiri, Darshan Madhav Sonde, Bita Amirian, Ali Bozorgi

Read the Full Article on EP Europace

Ali Bozorgi

Title 2: Risks of discontinuation of anticoagulation after atrial fibrillation ablation in high-risk patients

Authors: Giuseppe Boriani, Gianluca Botto, Davide Antonio Mei

Read the Full Article on EP Europace

Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace

Stay updated on all scientific advances with Hemostasis Today.

2024 ESC Guidelines Ali Bozorgi ALONE‑AF Amir Nasrollahizadeh Anoop Gurram Anticoagulation Anya Patel Arash Arya Atrial Fibrillation Atrial Fibrillation Ablation Bita Amirian Blood Darshan Madhav Sonde Davide Antonio Mei Ehsan Amini-Salehi ESC Journals Gianluca Botto Giuseppe Boriani Headlines Health Hematology Hemostasis News Hemostasis Today Javad Nadali Maryam Jafari Medicine Negin Letafatkar OCEAN Oral Anticoagulation Payam Kabiri Sandeep Samethadka Nayak Seyedeh Mohadese Mosavi Mirkalaie Shahriar Ghodous TIA University of Modena
NewsFeed